Capstone Investment Advisors
CTXR icon

Capstone Investment Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

Capstone Investment Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,659
Closed -$74K – 1744
2021
Q1 		$74K Buy
+1,659
New +$66.1K ﹤0.01% 1572

Other funds holding CTXR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capstone Investment Advisors's CTXR Position: Q2 2021 in Review

Capstone Investment Advisors sold out of Citius Pharmaceuticals (CTXR) in Q2 2021, closing a stake of 1,659 shares — an estimated $74K sold.

Capstone Investment Advisors first reported a position in CTXR in Q1 2021 and held it in 1 quarter. The position peaked at $74K in Q1 2021. 73 funds tracked by Wall St. Rank hold CTXR as of Q2 2021.

  • Capstone Investment Advisors reported no remaining Citius Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Capstone Investment Advisors sold 1,659 Citius Pharmaceuticals shares in Q2 2021, an estimated $74K.
  • Capstone Investment Advisors first reported a position in Citius Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Capstone Investment Advisors's Citius Pharmaceuticals position peaked at $74K in Q1 2021.
  • 73 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2021.

Based on Capstone Investment Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.